RER1.F Recordati Industria Chimica e Farmaceutica S.p.A

Healthcare Pharmaceuticals Frankfurt Exchange
52.50 EUR
Close of Nov 13, 2026
42.82 53.50
Market cap
EUR 10.9B
P/E
20.9x
P/B
5.12x
ROE
23.2%
Dividend yield
2.45%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RER1.F undervalued?

Graham number
Price52.50
Graham value24.06
Premium118.2%

RER1.F trades 118.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Recordati Industria Chimica e Farmaceutica S.p.A fundamental analysis

No fundamental analysis for Recordati Industria Chimica e Farmaceutica S.p.A yet.

Recordati Industria Chimica e Farmaceutica S.p.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Recordati Industria Chimica e Farmaceutica S.p.A

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular m…

Full company profile